{"title":"[Radiation Protection Against Exposure from Patients Receiving <sup>131</sup>I-MIBG and Released from Radiation Treatment Room].","authors":"Anri Inaki, Hiroshi Wakabayashi, Daiki Kayano, Seigo Kinuya","doi":"10.18893/kakuigaku.tr.2106","DOIUrl":null,"url":null,"abstract":"<p><p><sup>131</sup>I-3-iodobenzylguanidine or <sup>131</sup>I-iobenguane (3-(<sup>131</sup>I) iodobenzylguanidine or <sup>131</sup>I-iobenguane [<sup>131</sup>I-MIBG]) is a radioactive agent that is specifically accumulated in tumor cells such as pheochromocytoma and neuroblastoma. Due to its cytotoxic beta ray emitted from <sup>131</sup>I, it has been developed as an agent for radioisotope therapy and some researchers have reported its effectiveness. In this study, based on the patients' data from previous clinical trials of <sup>131</sup>I-MIBG therapy, we evaluated the radiation safety for public exposure caused by radiation emitted from patients who received <sup>131</sup>I-MIBG. In results, it was considered that public exposure and medical exposure of visitors and caregivers to the patients were less than their dose limit and dose constraint by complying the current criteria of the release of patients after therapy with <sup>131</sup>I.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kaku igaku. The Japanese journal of nuclear medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18893/kakuigaku.tr.2106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
131I-3-iodobenzylguanidine or 131I-iobenguane (3-(131I) iodobenzylguanidine or 131I-iobenguane [131I-MIBG]) is a radioactive agent that is specifically accumulated in tumor cells such as pheochromocytoma and neuroblastoma. Due to its cytotoxic beta ray emitted from 131I, it has been developed as an agent for radioisotope therapy and some researchers have reported its effectiveness. In this study, based on the patients' data from previous clinical trials of 131I-MIBG therapy, we evaluated the radiation safety for public exposure caused by radiation emitted from patients who received 131I-MIBG. In results, it was considered that public exposure and medical exposure of visitors and caregivers to the patients were less than their dose limit and dose constraint by complying the current criteria of the release of patients after therapy with 131I.
期刊介绍:
The main scope of JSNM is the appropriate development of the application of radioactive substances and stable nuclides in medicine. Towards this scope, JSNM promotes the exchange of idea and information, and researches in nuclear medicine. JSNM are interested in the international collaboration for the development of nuclear medicine. Through the activities, JSNM contributes to the medicine, as well as humanity, not only in Japan but also in any countries over the world.